ZEO ScientifiX Provides Business Update to Stockholders and the Investment Community
ZEO ScientifiX (OTCQB:ZEOX) has provided a comprehensive business update highlighting several key achievements and future plans. The company successfully completed Phase I clinical trials for its flagship product Zofin™ and is now positioned to pursue Phase II trials targeting multiple indications.
Notable developments include significant growth in sales of their PPX™ product, with revenue increasing by approximately $474,000 for the fiscal year ended October 31, 2024. The company established strategic partnerships with healthcare providers, including Physicians Group, , which operates 75 clinics.
In December 2024, ZEO launched ZEO HAIR GROW™ in collaboration with Exotropin , targeting the hair loss market. The company operates a cGMP FDA compliant research facility and has secured patents for their amniotic fluid product and PPX™ technology. Looking ahead to 2025, ZEO aims to advance clinical trials and is in negotiations for funding to commence Phase II trials as early as Q2 2025.
ZEO ScientifiX (OTCQB:ZEOX) ha fornito un aggiornamento aziendale completo evidenziando diversi risultati chiave e piani futuri. L'azienda ha completato con successo la fase I degli studi clinici per il suo prodotto di punta Zofin™ ed è ora pronta a perseguire gli studi di fase II mirati a più indicazioni.
Sviluppi degni di nota includono una crescita significativa delle vendite del loro prodotto PPX™, con un aumento dei ricavi di circa 474.000 dollari per l'anno fiscale chiuso il 31 ottobre 2024. L'azienda ha stabilito partnership strategiche con fornitori di assistenza sanitaria, inclusi i Physicians Group, che gestiscono 75 cliniche.
Nel dicembre 2024, ZEO ha lanciato ZEO HAIR GROW™ in collaborazione con Exotropin, mirando al mercato della perdita dei capelli. L'azienda gestisce una struttura di ricerca conforme alla cGMP e alla FDA e ha ottenuto brevetti per il loro prodotto a base di fluido amniotico e tecnologia PPX™. Guardando al 2025, ZEO punta a far avanzare gli studi clinici ed è in trattative per il finanziamento per avviare gli studi di fase II già nel secondo trimestre del 2025.
ZEO ScientifiX (OTCQB:ZEOX) ha proporcionado una actualización empresarial integral resaltando varios logros clave y planes futuros. La compañía completó con éxito los ensayos clínicos de fase I para su producto insignia Zofin™ y ahora está en posición de avanzar a los ensayos de fase II con múltiples indicaciones.
Desarrollos notables incluyen un crecimiento significativo en las ventas de su producto PPX™, con ingresos que aumentaron aproximadamente $474,000 para el año fiscal que finalizó el 31 de octubre de 2024. La compañía estableció asociaciones estratégicas con proveedores de atención médica, incluido el Physicians Group, que opera 75 clínicas.
En diciembre de 2024, ZEO lanzó ZEO HAIR GROW™ en colaboración con Exotropin, dirigiéndose al mercado de la pérdida del cabello. La empresa opera una instalación de investigación que cumple con las normativas cGMP y FDA y ha asegurado patentes para su producto de líquido amniótico y tecnología PPX™. Mirando hacia 2025, ZEO tiene como objetivo avanzar en los ensayos clínicos y está en negociaciones de financiamiento para comenzar los ensayos de fase II tan pronto como en el segundo trimestre de 2025.
ZEO ScientifiX (OTCQB:ZEOX)는 여러 주요 성과와 향후 계획을 강조하는 종합적인 비즈니스 업데이트를 제공했습니다. 이 회사는 대표 제품 Zofin™에 대한 1상 임상 시험을 성공적으로 완료했으며 이제 여러 적응증을 targeting하기 위한 2상 시험을 추진할 준비가 되었습니다.
주목할 만한 발전에는 PPX™ 제품의 매출이 약 474,000달러 증가하여 2024년 10월 31일 종료된 회계 연도 회계 기준으로 상당한 성장을 이루었다는 것이 포함됩니다. 이 회사는 75개 클리닉을 운영하는 Physicians Group를 포함한 의료 제공자와 전략적 파트너십을 구축했습니다.
2024년 12월, ZEO는 Exotropin과 협력하여 ZEO HAIR GROW™를 출시하여 탈모 시장을 겨냥했습니다. 이 회사는 cGMP와 FDA 기준을 준수하는 연구 시설을 운영하고 있으며, 자궁내막과 PPX™ 기술에 대한 특허를 확보했습니다. 2025년을 바라보며 ZEO는 임상 시험을 진행하고 2025년 2분기에는 2상 시험을 시작하기 위한 자금 조달 협상을 진행 중입니다.
ZEO ScientifiX (OTCQB:ZEOX) a fourni une mise à jour d'entreprise complète soulignant plusieurs réalisations clés et plans futurs. L'entreprise a réussi à compléter les essais cliniques de phase I pour son produit phare Zofin™ et est désormais prête à poursuivre les essais de phase II ciblant plusieurs indications.
Les développements notables incluent une croissance significative des ventes de leur produit PPX™, avec des revenus augmentant d'environ 474 000 dollars pour l'exercice clos le 31 octobre 2024. La société a établi des partenariats stratégiques avec des fournisseurs de soins de santé, y compris le Physicians Group, qui gère 75 cliniques.
En décembre 2024, ZEO a lancé ZEO HAIR GROW™ en collaboration avec Exotropin, ciblant le marché de la perte de cheveux. L'entreprise exploite une installation de recherche conforme à la cGMP et à la FDA et a obtenu des brevets pour son produit à base de liquide amniotique et sa technologie PPX™. En regardant vers 2025, ZEO vise à faire progresser les essais cliniques et est en négociations pour un financement afin de commencer les essais de phase II dès le deuxième trimestre 2025.
ZEO ScientifiX (OTCQB:ZEOX) hat ein umfassendes Unternehmensupdate bereitgestellt, das mehrere wichtige Erfolge und zukünftige Pläne hervorhebt. Das Unternehmen hat die Phase-I-Studien für sein Flaggschiffprodukt Zofin™ erfolgreich abgeschlossen und ist nun bereit, Phase-II-Studien mit mehreren Indikationen zu verfolgen.
Bemerkenswerte Entwicklungen umfassen ein signifikantes Wachstum der Verkaufszahlen ihres Produkts PPX™, wobei die Einnahmen für das am 31. Oktober 2024 endende Geschäftsjahr um etwa 474.000 US-Dollar gestiegen sind. Das Unternehmen hat strategische Partnerschaften mit Gesundheitsdienstleistern etabliert, darunter die Physicians Group, die 75 Kliniken betreibt.
Im Dezember 2024 brachte ZEO ZEO HAIR GROW™ in Zusammenarbeit mit Exotropin auf den Markt, das auf den Haarausfallmarkt abzielt. Das Unternehmen betreibt eine nach cGMP und FDA konforme Forschungseinrichtung und hat Patente für sein Produkt mit Fruchtwasser und die PPX™-Technologie gesichert. Für 2025 plant ZEO, die klinischen Studien voranzutreiben und befindet sich in Verhandlungen über Finanzmittel, um die Phase-II-Studien bereits im zweiten Quartal 2025 zu starten.
- Successful completion of Phase I clinical trials for Zofin™
- Revenue increase of $474,000 for PPX™ product in FY2024
- Strategic partnership with Physicians Group (75 clinics)
- Patent approvals for amniotic fluid product and PPX™ technology
- Launch of new product ZEO HAIR GROW™
- Requires additional funding to commence Phase II trials
- Multiple IND applications yet to commence trials
- Only holds minority interest in Exotropin
FORT LAUDERDALE, FL / ACCESS Newswire / February 11, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company focused on the research and development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine and the development and sales of biologic products used in topical aesthetic applications, today provided a business update to stockholders and the investment community.
The Opportunity
As of the end of 2024, the Company has accomplished several key objectives, which we believe positions us for continued success in 2025 and beyond. We are most excited about the successful completion of our Phase I clinical trials for Zofin™, the Company's flagship proprietary product, which puts us in the enviable position of being able to pursue Phase II clinical trials, targeting multiple indications to address unmet medical needs in both acute and chronic conditions. The successful completion of one or more Phase II clinical trials would represent a new and significant valuation inflection point for our Company. We believe that our robust clinical trial portfolio provides us with the opportunity to become an industry leader in developing and providing biologic therapeutics for the regenerative medicine market, projected to reach nearly
Research and Clinical Trials
ZEO's goal has always been to obtain FDA approval to market our novel therapeutics. In this regard, we remain committed in being a leader in the field when it comes to research, quality, safety and compliance. All of our products undergo rigorous testing to ensure safety, efficacy and consistency. The Company operates a state-of-the-art cGMP FDA compliant research and processing facility and we have built a dedicated team of eminently qualified researchers and extremely experienced management.
In addition to the successful Phase I safety trials completed for Zofin™, ZEO has yet to commence other previously FDA approved Investigational New Drug (IND) applications to conduct combined Phase I/II Randomized, Double Blinded, Placebo clinical trials utilizing Zofin™ for specific indications, including Osteoarthrosis and COPD. Based on the past success of our Phase I safety trials using Zofin™, combined with additional research and insights as to the mechanism of action of Zofin™ in treating specific indications, we intend to amend our INDs to focus on Phase II objectives with more observable and measurable outcomes. We believe that these amendments will streamline our efforts and increase the likelihood of success and reduce the overall costs of those clinical trials. We are also actively exploring several other additional indications for which we intend to seek IND approvals in the near future.
ZEO has also been very active in arranging for IRB approved studies with leading medical practices and clinics to gather the data on the safety and efficacy of our products, aimed at supporting decisions by those practices to use our products to treat specific indications and for us to be in a position to secure additional FDA approvals for INDs that target those indications.
Patent Prosecution
As further validation of our advanced research and unique and proprietary product portfolio, during the past year we were issued patents for (a) our amniotic fluid product, which incorporates certain proprietary techniques used for processing perinatal fluid and treating a disease; and (b) the proprietary techniques of our peripheral blood derived ("PPX™") product used in the administration of blood-derived exosomes to treat pain. We will continue to seek additional patent opportunities, including continuation applications of our issued patents to further expand and strengthen our patent portfolio to assure that our intellectual property remains proprietary.
Zeo believes that we are a leader in biologic research, with one of the most comprehensive research and clinical trial portfolios in the industry.
The Growth Of Our PPX™ Autologous Product
During 2024, the Company realized significant growth in the sales of our novel PPX™ product, with revenue increasing by approximately
Growing Partnership Relationships
During 2024, we were successful in establishing strategic partnerships with several large healthcare providers, including Physicians Group, LLC, a multi-state provider organization that together with its affiliated entities, operates 75 clinics and employees over 750 clinical personnel treating between 1500 - 2000 patients per month many of whom seek care for musculoskeletal conditions.
We believe that these partnerships uniquely position us to advance our research objectives through collaboration on future clinical trials that will focus on certain health indications commonly treated by these providers where our products may demonstrate greater therapeutic benefit than currently-available and previously tried treatments. Additionally, these partnerships provide us with access to highly informed and experienced clinicians as well as potentially qualified subjects for enrollment in our planned clinical trials.
Expansion Into Topical Aesthetics
During 2023, we acquired a minority interest in Exotropin LLC, a privately held developer of advanced cosmeceuticals utilizing engineered exosomes and other proprietary technology, in an effort to accelerate access the medical aesthetic market and in partnership create new topical aesthetic formulations and delivery systems. During December 2024, Zeo and Exotropin launched the collaborative topical product "ZEO HAIR GROW™ Powered By Exotropin™" for physicians and med spas. ZEO HAIR GROW™ powered by Exotropin™ is aimed to provide tools practitioners can utilize in the multifactorial approach to address the highly lucrative and expanding hair loss market which is becoming more prevalent for both women as well as men. According to the 2020 Practice Census published by the International Society of Hair Restoration Surgery, it is estimated that 35 million men and 31 million women in the United States are affected by hair loss.
ZEO HAIR GROW™ powered by Exotropin™ is a formulated hair system designed for physicians by physicians and scientists. Unlike other hair loss products in the market, ZEO HAIR GROW™ powered by Exotropin™ combines the synergistic and complementary power of extracellular vesicles derived from several sources (amniotic fluid, adipose stromal cells, and the aloe vera plant), to optimize the health of the scalp and support a thicker, fuller head of hair.
The Company is continuing to seek other opportunities to distribute our proprietary ingredients be used in topical aesthetic applications in the practitioner offices, including partnerships with large aesthetic device manufacturers.
Educational Initiatives
ZEO recognizes the growing demand by healthcare providers for comprehensive information on biologic therapies and we are dedicated to playing our part in this process. To support this mission, we recently commenced a monthly educational series, "The Future of Biologic Medicine: Expert-Led Discussions and Case Studies," designed to share insights, facilitate collaboration, develop relationships with providers and foster industry leadership.
We believe that ZEO is among the first clinical-stage biopharmaceutical companies to introduce this type of structured educational program. By equipping healthcare providers with cutting-edge knowledge, ZEO aims to empower practitioners and expand patient access to innovative biologic treatments.
Looking Ahead to 2025
Our priorities for 2025 are crystal clear: We are committed to advancing our clinical pipeline, launching Phase II trials for Zofin™, and initiating studies for other promising indications to be treated from products in our pipeline. We are currently in negotiations with several sources to fund the commencement of a recently approved Phase II IND and are hopeful that we can be successful in securing the needed financing to commence the trial as early as the second calendar quarter of 2025. In addition to clinical advancements, we expect to continue to see continued sales growth from our PPX and ZEO HAIR GROW™ powered by Exotropin™ products and from other new biologic product introductions.
Furthermore, we are optimistic regarding potential policy shifts under the new Trump administration, which may lead to a more proactive regulatory approach toward regenerative medicine. Such changes could provide more efficient FDA approval pathways for ZEO's therapeutic products targeting specific indications.
The Board of Directors and executive leadership team extends their gratitude to the Company's stockholders for their continued trust and support. With a vision to redefine the standards of regenerative medicine and creating a lasting impact on patient care, ZEO looks forward to a transformative year ahead.
About ZEO ScientifiX, Inc.
ZEO ScientifiX is a clinical-stage biopharmaceutical company primarily focused on developing innovative biological therapeutics for regenerative medicine and the treatment of degenerative diseases. We are driven by a commitment to advance the frontiers of regenerative medicine and biologic therapeutics, delivering meaningful solutions for patients and providers worldwide. Our proprietary products, including (a) Zofin™, which are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and (b) Patient Pure X™ ("PPX™"), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood. During November 2024, the Company announced that it was launching the first planned collaborative product with Exotropin; "ZEO HAIR GROW™ Powered By Exotropin™", a proprietary topical physician formulated hair regrow system. The Company's proprietary products are manufactured in an FDA-registered, cGMP-compliant laboratory. To learn more, please visit https://zeoscientifix.com.
Forward-Looking Statements
Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will," "believes," "expects," "potential," or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. No assurances can be given that the Company will be successful in its research initiatives. In addition, no assurances can be given that our research initiatives will increase the price of our common stock to a level that is attractive to brokerage houses and institutional investors. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations, including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. ZEO has no intention and specifically disclaims any duty to update the information in this press release.
Contact Information
ZEO Investor Relations
Jacqueline Domenech
1-888-963-7881
IR@zeoscientifix.com
SOURCE: ZEO ScientifiX, Inc.
View the original press release on ACCESS Newswire
FAQ
What were the key financial results for ZEOX's PPX™ product in 2024?
When does ZEOX plan to begin Phase II clinical trials for Zofin™?
What new product did ZEOX launch in December 2024?
What patents did ZEOX secure in 2024?
How many clinics does ZEOX's partner Physicians Group operate?
